Journal-based CME is available every month through the study of designated articles within PM&R, the official scientific journal of the American Academy of Physical Medicine and Rehabilitation.
Learning Objectives
After completing this enduring material, the participant should be able to:
- Demonstrate an increase in, or affirm, their knowledge of clinical medicine and research.
- Evaluate the appropriateness of the clinical information as it applies to the provision of patient care.
- When appropriate, implement changes in practice relevant to the content of the article.
Accreditation Statement
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Credit Designation
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement
In accordance with ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, AAPM&R requires all individuals who are in a position to affect the strategic direction of AAPM&R and/or control the content of an educational activity to disclose all financial relationships with any ineligible company within the last 24 months. The ACCME defines an “ineligible company” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Disclosures are made in written form prior to the start of the educational activity, and any potential conflicts of interest that exist are mitigated prior to the start of the activity through AAPM&R’s Conflict of Interest Disclosure and Resolution Policy Process. Individuals in a position to affect the strategic direction of AAPM&R and/or control content and their disclosed financial relationships are listed below.
No other planners, faculty, or individuals in control of content disclosed any relevant financial relationships. Through the planning process, all relevant financial relationships have been mitigated.
Principal Faculty:
Editor-in-Chief: Janna Friedly, MD: Disclosed no relevant financial relationships.
Article Authors:
Jacqueline Weisbein DO reports consulting fees from SI-Bone and Abbott; and payment or honoraria for lectures/presentations from AbbVie and Vertex.
Timothy Davis MD reports consulting fees from SI-Bone, Medtronic, Boston Scientific, Spine BioPharma, Spinal Simplicity, VIVEX, DiscGenics, Saluda, Abbott, Kolon TissueGene, and Tenex Health; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Medtronic, VIVEX, Mesoblast, SI-Bone, Abbott, Spine Bio-Pharma, Spinal Solutions, NatureCell, DiscGenics, Kolon TissueGene, and Boston Scientific; and support for attending meetings from SI-Bone.
Douglas Beall MD reports consulting fees from SI-Bone; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Medtronic, ReGelTec, Nanofuse, Talosix, Spinal Simplicity, Spark Biomedical, Smart Soft, Tissue Tech, Bronx Medical, Thermaquil, Vivex, Genesys, SetBone Medical, Amber Implants, Cerapedics, SpinaFX, SIBone, AIS Healthcare, Maho MT (US), and US Healthcare; and support for attending meetings and/or travel from Stryker, Medtronic, Boston Scientific, Merit, Avanos, Piramal, Genesys, Eliquence, AIS Healthcare, and Amgen. Robyn Capobianco reports stock or stock options in SI-Bone.
Jack Smith MD reports consulting fees and payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from SIBone.
Caroline Harstroem MD reports grants or contracts and research support from SIBone related to the STACI study, including payments to Research/Consulting LLC.
Daniel Kloster MD reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbott, Spinal Simplicity, NeuroOne, Boston Scientific, and Nevro; and stock or stock options from NeuroOne, Spinal Simplicity, and inFormed Consent.
Morteza Rabii DNP, APRN reports grants or contracts from Abbott; consulting fees from Abbott Neuromodulation, SI-Bone, Spinal Simplicity, and inFormed Consent.
Robyn Capobianco PhD: Disclosed no relevant financial relationships.
Ramana Naidu MD reports participation on a data safety monitoring board for SI-Bone.
Michael Harned MD: Disclosed no relevant financial relationships.
Christopher Mallard MD reports grants or contracts from Medtronic; and consulting fees from Johnson & Johnson and SI-Bone.
the STACI investigators: Disclosed no relevant financial relationships.
AAPM&R Medical Education Committee
Rachel A. Brakke Holman, MD, Chair: Disclosed no relevant financial relationships.
Sarah M. Eickmeyer, MD: Disclosed no relevant financial relationships.
Chelsea D. Frost, MD, MS: Disclosed no relevant financial relationships.
David J. Haustein, MD, MBA: PM Consulting, Expert Medical Consulting: Ownership or Partnership; Greene County Medical Society Executive Council, Missouri State Medical Foundation Board: Non-remunerative Positions of Influence
Sarah K. Hwang, MD: Disclosed no relevant financial relationships.
Ravi E. Kasi, MD: Disclosed no relevant financial relationships.
Caroline Pupke, DO: Disclosed no relevant financial relationships.
Monica E. Rho, MD: Disclosed no relevant financial relationships.
McCasey R. Smith, MD: Disclosed no relevant financial relationships.
Jennifer A. Soo Hoo, MD: Disclosed no relevant financial relationships.
Brionn K. Tonkin, MD: Disclosed no relevant financial relationships.
Stephanie Tow, MD: Disclosed no relevant financial relationships.
Justin L. Weppner, DO: Disclosed no relevant financial relationships.
Alexandra G. Wolfe, DO: Disclosed no relevant financial relationships.
FDA Disclosures
Any faculty member for this activity who intends to discuss or demonstrate any pharmaceutical or medical device for which FDA clearance has not been approved, will verbally disclose the FDA’s classification at the beginning of their presentation or demonstration.